The 100 000 Genome Project aims to develop a diagnostics platform by introducing whole genome sequencing (WGS) into clinical practice. Samples from patients with chronic lymphocytic leukaemia were subjected to WGS. WGS detection of single nucleotide variants and insertion/deletions were validated by targeted next generation sequencing showing high concordance (96Á3%), also for detection of sub-clonal variants and low-frequency TP53 variants. Copy number alteration detection was verified by fluorescent in situ hybridisation and genome-wide single nucleotide polymorphism array (concordances of 86Á7% and 92Á9%, respectively), confirming adequate sensitivity by WGS. Our results confirm that WGS can provide comprehensive genomic characterisation for clinical trials, drug discovery and, ultimately, precision medicine.
In chronic lymphocytic leukaemia (CLL), deletions and/or mutations of TP53, including subclonal mutations, are associated with short overall survival, poor response to conventional chemo-immunotherapy (CIT) (Pospisilova et al, 2012 (Pospisilova et al, , 2016 and direct therapy choice. Guidelines for routine diagnostic screening of TP53 alterations currently recommend a combination of fluorescent in situ hybridisation (FISH) and Sanger Sequencing for copy number alteration (CNA), single nucleotide variant (SNV) or insertion/deletion (InDels) detections, respectively (Pospisilova et al, 2012) . However, these techniques lack sensitivity, are labour intensive and fail to detect additional emerging predictive markers, including genomic complexity (GC) (Anderson et al, 2017) and IGHV status (Rosenquist et al, 2017) .
In addition, other genome-wide mutation signatures, including the number of subclonal drivers and hotspots in non-coding regulatory regions, have been associated with poor prognosis, and sequencing efforts have revealed a growing number of driver genes, for which targeted therapies are under development (i.e. NOTCH1, SF3B1 and ATM) (Landau et al, 2013; Puente et al, 2015) . It is therefore likely that, in the emerging era of precision medicine, future diagnostic tools that are able to detect these different types of genomic aberrations in a single test have to be developed and introduced into clinical diagnostics.
The 100 000 Genomes Project in the United Kingdom aims to develop such a future-proof diagnostics platform by introducing whole genome sequencing (WGS) into clinical practice. This pilot sub-study therefore aimed to provide a clinical-grade validation of results obtained from short read WGS as part of the CLL Genomics England Pilot using a clinically accredited targeted gene panel or gold standard FISH technique and genome-wide high-resolution arrays for detection of SNVs, InDels or CNAs, respectively.
Materials and methods

Patient material
Tumour (peripheral blood) and germline (GL; saliva) samples from 64 patients with CLL recruited into the ADMIRE ; n = 33) and ARCTIC ; n = 31) studies and who were consented for WGS, were randomly selected (total n = 250; REC 09/H1306/54). Baseline patient characteristics are provided in Table SI. WGS WGS was performed on peripheral blood tumour and GL samples on the HiSeqX (Illumina, Inc., San Diego, CA, USA) according to standard operating procedures and using the bio-informatics pipeline developed for the Genomics England Main Programme analysis. Sequencing reads were aligned to the Human Genome Assembly GRCh37 using ISAAC Whole Genome Sequencing v4 (https://github.com/Illumina/isaac2); Strelka 2.4.7 (https://github.com/Illumina/strelka) was used for detection of somatic SNV and InDels, and Manta 0.28.0 and Canvas 1.3.1 for detection of somatic CNAs (Illumina, Inc., San Diego, CA, USA). Somatic variants were filtered to retain only either the ones annotated with the following Variant Effect Predictor consequences: transcript ablation, splice acceptor variant, splice donor variant, stop gained, frameshift variant, stop lost, start lost, transcript amplification, inframe insertion, inframe deletion, missense variant, protein-altering variant, splice region variant, incomplete terminal codon variant. For the purpose of this pilot study, only variants in the 11 genes included in a targeted resequencing (TGS) panel accredited for clinical diagnostics were selected for further analysis (Fig 1) . Variants discrepant against TGS outcome were visually inspected using Integrated Genomics Viewer (IGV; https://github.com/igvteam/igv).
TGS
A clinically accredited TGS panel was used for validation of the variant detection performance of WGS. A TruSeq Custom Amplicon (TSCA, Illumina, Inc., San Diego, CA, USA) panel was designed, targeting mutational hotspots in nine CLL driver genes. For samples in which an EGR2 and/or a RPS15 variant was detected with WGS, re-sequencing was performed using an expanded targeted panel including 11 driver genes (Fig 1) . Further details are provided in the Data S1. , excluding MED12 and MYD88, which were also included in gene list, but were not concordantly detected and therefore not listed in (B). (A) Reasons for discrepancies between the outcome of the WGS versus TGS platforms prior to IGV analysis. After IGV control three variants remained discrepant: two because they were not covered by the TGS design and one due to low total reads by WGS (i.e. below filtering threshold). Additional information to be found in Genome-wide SNP platform hybridizations and analysis (array) Illumina HumanOmni2.5-8 Beadships (Illumina, Inc., San Diego, CA, USA) were used according to the manufacturer's instructions. Data was analysed as previously described (Knight et al, 2012) .
FISH
FISH was performed as previously described Munir et al, 2017) .
Statistical analysis
Concordance of variant allele frequencies (VAFs) reported by WGS and TGS was evaluated with Pearson's correlation test. An outlier was defined as 1Á5 9 upper quartiles of mean % coefficient of variance of paired VAF (Renze, 2017) . Kaplan and Meier survival analysis with log-rank test was applied for time to progression (TTP) versus GC using GraphPad Prism V7.0a (GraphPad Software Inc., La Jolla, CA, USA). A P < 0Á05 was considered statistically significant.
Results and discussion
WGS was performed on paired tumour and GL control samples. An average reading depth of 104Á69 [standard deviation (SD) 11Á89] for tumour samples and 33Á59 (SD 3Á29) for paired GL controls was reached; a coverage previously shown to ensure adequate sequencing sensitivity (down to 10% VAF) (Alioto et al, 2015) . Eleven CLL driver genes were evaluated (Fig 1) , and 71 variants (SNVs/InDels, VAF of ≥4%) were detected by WGS in 41 subjects (n = 41/64; 64Á1%). Without visual inspection, 100% concordance between the technologies was shown for EGR2, RPS15 and XPO1 and, in total, for 55 variants (n = 55/82; 67Á1%). Reasons for discrepancies are shown in Fig 1A. Discordant variants investigated using IGV resulted in an increase of concordant calls to 96Á3% (79 of 82 variants detected by both techniques combined and available for evaluation; 3 variants detected by WGS but could not be confirmed by TGS due to exhaustion of tissue sample), clearly proving the WGS coverage to be comparable to TGS (Table SII) . Reassuringly, evaluation of the VAF reported by WGS and TGS showed a high concordance for both subclonal variants and low-frequency TP53 variants down to ≥2% VAF; far lower than previously reported for WGS (Fig 1B, C) (Rehm, 2013) . WGS identified 52 CNAs of previously reported clinical significance in CLL (D€ ohner et al, 2000) . Verification by FISH showed a concordance of 86Á7% (n = 26/30; Fig 2A) and Array showed a concordance with WGS of 92Á9% (n = 52/56; Fig 2B) , confirming adequate sensitivity for CNA (losses and gains) detection by WGS.
GC has been associated with adverse prognosis in CLL, even in the era of targeted therapy (Anderson et al, 2017) . GC assessment by conventional karyotyping is technically difficult, labour intensive and costly. Array-based studies have reported a significantly worse prognosis in CLL patients with GC defined by at least 3 or 4 CNAs (Ouillette et al, 2011; Knight et al, 2012) . We evaluated GC by expanding our validation to genome-wide CNA detection (including acquired CNAs > 50 kB) by Array and WGS (n = 60 subjects). Using Array, a total of 228 CNAs was detected versus 192 by WGS corresponding to an overall concordance of 84Á2% (n = 192/228) (Table SIII) . GC (defined as detection of ≥4 CNAs, (Yu et al, 2017) was concordantly detected by the techniques in 88Á3% (n = 15/17) of the patients (Fig 2C) . GC determined by Array was significantly associated with shorter TTP (P = 0Á029) and the same trend was shown for GC determined by WGS (P = 0Á07) with discrepant outcome in one subject (Fig 2D) . However, of note is an overrepresentation of TP53/del17p lesions in cases with GC (n = 6/7, 85Á7%) potentially explaining the association with short TTP.
Our results show that WGS provides technically accurate detection of SNVs, InDels and clinically significant CNAs. Discrepancies were, in the majority of cases, explained by a lack of consensus of the bioinformatics pipelines used for TGS, WGS and Array, a problem previously highlighted by others (Alioto et al, 2015) that urgently calls for stringent standardisation of bio-informatics algorithms and filters, not least to improve accurate calling of chromosomal aberrations. We show that the concordance rates between the two techniques improved, from 67Á1% to 96Á3%, after visual inspection of all discordant variants, which confirm that the sequencing techniques adequately detect mutations and larger genomic events. It also argues for a requirement to complement automated sequencing analysis with skilled evaluation by a trained specialist in order to get clinically valid results. An advantage with the WGS strategy used here, confirmed by our findings, is that GL variants are detected and hence not reported. Important efforts to standardize targeted sequencing in CLL are ongoing (Pospisilova et al, 2016) . However, use of targeted approaches prevents the development of future prediction tools to include genome-wide markers. The increased availability of targeted therapies calls for an ever increasingly comprehensive panel design to cover a larger number of targets and types of mutations including low frequency variants (Konig et al, 2015) , making clinical grade validation of targeted panels that is compliant with accreditation standards too cumbersome and cost-and timeconsuming (Rehm, 2013) . Moreover, an increasing body of evidence suggests GC as important prognostic factors (Ouillette et al, 2011; Puente et al, 2015; Yu et al, 2017 ) that cannot be revealed by targeted approaches. The overall cost of large panels or whole exome sequencing has become comparable to WGS (Rehm, 2013) , not least when considering that separate analyses for chromosomal aberrations will not be needed when using WGS. Finally, WGS provides a futureproof approach to diagnostics as the results can be used for biomarker discovery.
In conclusion, we present the first clinical-grade validation of results obtained from WGS as part of the CLL Genomics England Pilot. We show that WGS confidently detects all types of clinically relevant mutations. Our results confirm that WGS can provide clinically useful and comprehensive genomic characterisation for clinical trials, drug discovery and ultimately precision medicine. DB, PA, AS, JB, DB, PH, JT, MC and AS performed the research and/or contributed patient samples and associated data. All authors read and agreed to the final version of the manuscript.
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